Drug intelligence / Profile preview

RM803

Development stage: Preclinical
Lead developer: Guangzhou Reforgene Medicine
Modality: CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies
Administration: Intravenous

Overview

RM803 is an investigational **in vivo gene-editing** therapeutic candidate currently in the preclinical stage of development. It is being developed by **Guangzhou Reforgene Medicine**, a biotechnology company specializing in CRISPR-based genetic medicines. The program is designed to address undisclosed indications within the **cardiovascular and hepatic** therapeutic areas. As an in vivo gene-editing asset, RM803 likely utilizes a delivery system, such as lipid nanoparticles (LNPs) or viral vectors, to transport gene-editing machinery (e.g., CRISPR/Cas systems) directly to target tissues to achieve therapeutic modification of specific genetic sequences.

Beyond the preview

Go deeper on RM803.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RM803.

Explore the full profile